Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (öffnet neues Fenster)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Quelle‎: Eur J Haematol 1996;56(5):326-8.

Indiziert‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (öffnet neues Fenster)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (öffnet neues Fenster)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Quelle‎: Acta Haematol 1995;94(3):128-34.

Indiziert‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (öffnet neues Fenster)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (öffnet neues Fenster)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Quelle‎: Haematologica 2006;91(8):1076-83.

Indiziert‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (öffnet neues Fenster)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (öffnet neues Fenster)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Quelle‎: J Obstet Gynaecol 2007;27(1):82-3.

Indiziert‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (öffnet neues Fenster)

The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (öffnet neues Fenster)

Wang SW, Badami CD, Deitch EA.

Quelle‎: Am Surg 2009;75(12):1175-8.

Indiziert‎: PubMed 19999907

https://www.ncbi.nlm.nih.gov/pubmed/19999907 (öffnet neues Fenster)